Foghorn Therapeutics Inc.

9.40-0.0900-0.95%Vol 67.11K1Y Perf -47.90%
Jul 27th, 2021 15:25 DELAYED
BID9.40 ASK9.45
Open9.48 Previous Close9.49
Pre-Market- After-Market-
 - -%  - -
Target Price
23.50 
Analyst Rating
— — 0.00
Potential %
147.89 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12 mo.
-/-/- 
Value Ranking
★★     47.34
Insiders Value % 3/6/12 mo.
-/-/- 
Growth Ranking
 —    -
Insiders Shares Cnt. % 3/6/12 mo.
-/-/- 
Income Ranking
 —    -
Market Cap346.35M 
Earnings Rating
Price Range Ratio 52W %
2.03 
Earnings Date
2nd Apr 2021

Today's Price Range

9.399.55

52W Range

9.0128.26

Summary:

Sell

Technical Indicators: Neutral
Moving Averages: Strong Sell
Performance
1 Week
-3.85%
1 Month
-7.77%
3 Months
-17.48%
6 Months
-45.55%
1 Year
-47.90%
3 Years
-
5 Years
-
10 Years
-

TickerPriceChg.Chg.%
FHTX9.40-0.0900-0.95
AAPL146.68-2.3100-1.55
GOOG2 726.81-66.0800-2.37
MSFT286.17-2.8800-1.00
XOM57.70-0.7800-1.33
WFC45.120.11000.24
JNJ172.210.34000.20
FB366.38-6.0800-1.63
GE13.110.19001.47
JPM151.43-0.2200-0.15
Earnings HistoryEstimateReportedSurprise %
Q03 2020-2.12-3.12-47.17
----
----
----
----
----
----
----
Earnings Per EndEstimateRevision %Trend
----
----
----
----
Next Report Date-
Estimated EPS Next Report-0.66
Estimates Count2
EPS Growth Next 5 Years %-
Volume Overview
Volume67.11K
Shares Outstanding36.85M
Trades Count930
Dollar Volume529.31K
Avg. Volume107.08K
Avg. Weekly Volume35.52K
Avg. Monthly Volume76.25K
Avg. Quarterly Volume120.09K

Foghorn Therapeutics Inc. (NASDAQ: FHTX) stock closed at 9.49 per share at the end of the most recent trading day (a -1.86% change compared to the prior day closing price) with a volume of 24.73K shares and market capitalization of 346.35M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 85 people. Foghorn Therapeutics Inc. CEO is Adrian Gottschalk.

The one-year performance of Foghorn Therapeutics Inc. stock is -47.9%, while year-to-date (YTD) performance is -53.18%. FHTX stock has a five-year performance of %. Its 52-week range is between 9.01 and 28.26, which gives FHTX stock a 52-week price range ratio of 2.03%

Foghorn Therapeutics Inc. currently has a PE ratio of -1.40, a price-to-book (PB) ratio of 2.85, a price-to-sale (PS) ratio of 497.63, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -33.86%, a ROC of -37.69% and a ROE of -62.19%. The company’s profit margin is -%, its EBITDA margin is -10 444.60%, and its revenue ttm is $716.00 Thousand , which makes it $0.02 revenue per share.

Of the last four earnings reports from Foghorn Therapeutics Inc., there were 0 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $-0.66 for the next earnings report. Foghorn Therapeutics Inc.’s next earnings report date is -.

The consensus rating of Wall Street analysts for Foghorn Therapeutics Inc. is (), with a target price of $, which is 0.00% compared to the current price. The earnings rating for Foghorn Therapeutics Inc. stock is (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Foghorn Therapeutics Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Foghorn Therapeutics Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 10.68, ATR14 : 0.62, CCI20 : -65.34, Chaikin Money Flow : 0.01, MACD : -0.28, Money Flow Index : 45.83, ROC : -7.23, RSI : 41.96, STOCH (14,3) : 21.05, STOCH RSI : 0.10, UO : 55.53, Williams %R : -78.95), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Foghorn Therapeutics Inc. in the last 12-months were:

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
0
0
0
Moderate Buy
0
0
0
Hold
0
0
0
Moderate Sell
0
0
0
Strong Sell
0
0
0
Summary Rating---

Foghorn Therapeutics Inc.

Foghorn Therapeutics Inc is engaged in discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system, an untapped opportunity for therapeutic intervention. Its proprietary Gene Traffic Control platform gives us an integrated, mechanistic understanding of how the various components of the chromatin regulatory system interact, allowing it to identify, validate and potentially drug targets within the system. The company is developing FHD-286, a selective, allosteric ATPase inhibitor, and FHD-609, a protein degrader, to treat hematologic cancers and solid tumors.

CEO: Adrian Gottschalk

Telephone: +1 617 586-3100

Address: 100 Binney Street, Cambridge 02142, MA, US

Number of employees: 85

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

67%33%

Bearish Bullish

60%40%

Bearish Bullish

33%67%

News

Stocktwits